Parthenolide Overcomes Vemurafenib Resistance in Melanoma

Keyphrases

• Melanoma 100%
• Parthenolide 100%
• Vemurafenib Resistance 100%
• Heat Shock Protein 90 (Hsp90) 47%
• A375 31%
• Ferroptosis 21%
• STAT3 Signaling Pathway 10%
• Protein Level 10%
• Immunoblotting 10%
• Glutathione Peroxidase 4 (GPX4) 10%
• BRAF Inhibitor (BRAFi) 10%
• BRAF-mutant Melanoma 10%
• Mechanism of Action 5%
• Molecular Dynamics Simulation 5%
• Chinese Medicinal Herbs 5%
• MRNA Level 5%
• Anti-melanoma 5%
• Tumor Growth 5%
• Quantitative PCR 5%
• Mitochondrial Membrane Potential 5%
• Induced Apoptosis 5%
• Drug Target 5%
• ATP Synthase 5%
• Therapeutic Agents 5%
• Clinical Efficacy 5%
• C-Myc 5%
• AKT1 5%
• Promising Target 5%
• Melanoma Cells 5%
• ERK Pathway 5%
• Fe2+ 5%
• Xenograft 5%
• Molecular Docking 5%
• Approved Drugs 5%
• Chaperone 5%
• C-Src 5%
• Cycloheximide 5%
• Oncoprotein 5%
• Proteinase Inhibitor 5%
• Sesquiterpenes 5%
• S-phase Arrest 5%
• Valine 5%
• Glutamine 5%
• Insulin-like Growth Factor 1 Receptor (IGF1R) 5%
• Melanoma Patients 5%
• Nuclear factor-κB Pathway 5%
• Client Proteins 5%
• BRAF V600E mutant 5%
• Vemurafenib 5%
• V600E 5%
• BRAF V600E 5%
• Surface Plasmon Resonance Assay 5%
• Vemurafenib-resistant 5%
• Solute Carrier Family 7 Member 11 (SLC7A11) 5%
• Platelet-derived Growth Factor Receptor (PDGFR) 5%
• BRAF Gene 5%
• Morphological Signs 5%
• C-Raf 5%
• Disease Network Analysis 5%
• Piper 5%

Pharmacology, Toxicology and Pharmaceutical Science

• Melanoma 100%
• Parthenolide 100%
• Vemurafenib 100%
• Heat Shock Protein 90 47%
• Ferroptosis 21%
• Western Blot 10%
• GPX4 10%
• Diseases 5%
• Messenger RNA 5%
• Tumor Growth 5%
• Adenosine Triphosphatase 5%
• Ferrous Ion 5%
• Epidermal Growth Factor Receptor 5%
• Sesquiterpene 5%
• Cycloheximide 5%
• Oncoprotein 5%
• Immunoglobulin Enhancer Binding Protein 5%
• Glutamine 5%
• Valine 5%
• Chaperone 5%
• Surface Plasmon Resonance 5%
• Insulin-Like Growth Factor 1 5%
• Protein Synthesis Inhibitor 5%